Next Article in Journal
Wnt Signaling Pathway Is among the Drivers of Liver Metastasis
Previous Article in Journal
Assisting Difficult Liver Operations Using 3D Printed Models
Previous Article in Special Issue
The Cape Gooseberry Constituent Physalin B Ameliorates Nonalcoholic Steatohepatitis and Attenuates Liver Fibrosis
Review

Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension

by 1, 1,2,3,† and 1,2,3,*,†
1
Blacktown Clinical School, School of Medicine, Western Sydney University, Blacktown, NSW 2148, Australia
2
Blacktown Hospital, Blacktown, NSW 2148, Australia
3
Storr Liver Centre, The Westmead Institute for Medical Research, University of Sydney, Westmead, NSW 2145, Australia
*
Author to whom correspondence should be addressed.
These authors contribute equally to this work.
Academic Editor: Ralf Weiskirchen
Livers 2021, 1(3), 147-179; https://doi.org/10.3390/livers1030014
Received: 15 July 2021 / Revised: 3 September 2021 / Accepted: 6 September 2021 / Published: 9 September 2021
(This article belongs to the Special Issue Hepatic Fibrosis: From Pathogenesis to Clinical Management)
Antifibrotic therapies for the treatment of liver fibrosis represent an unconquered area of drug development. The significant involvement of the gut microbiota as a driving force in a multitude of liver disease, be it pathogenesis or fibrotic progression, suggest that targeting the gut–liver axis, relevant signaling pathways, and/or manipulation of the gut’s commensal microbial composition and its metabolites may offer opportunities for biomarker discovery, novel therapies and personalized medicine development. Here, we review potential links between bacterial translocation and deficits of host-microbiome compartmentalization and liver fibrosis that occur in settings of advanced chronic liver disease. We discuss established and emerging therapeutic strategies, translated from our current knowledge of the gut–liver axis, targeted at restoring intestinal eubiosis, ameliorating hepatic fibrosis and rising portal hypertension that characterize and define the course of decompensated cirrhosis. View Full-Text
Keywords: liver fibrosis; portal hypertension; microbiota; cirrhosis; chronic liver disease; gut–liver axis; bacterial translocation; hepatic macrophages; PRRs; TLRs liver fibrosis; portal hypertension; microbiota; cirrhosis; chronic liver disease; gut–liver axis; bacterial translocation; hepatic macrophages; PRRs; TLRs
Show Figures

Figure 1

MDPI and ACS Style

Kalo, E.; Read, S.; Ahlenstiel, G. Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. Livers 2021, 1, 147-179. https://doi.org/10.3390/livers1030014

AMA Style

Kalo E, Read S, Ahlenstiel G. Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. Livers. 2021; 1(3):147-179. https://doi.org/10.3390/livers1030014

Chicago/Turabian Style

Kalo, Eric, Scott Read, and Golo Ahlenstiel. 2021. "Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension" Livers 1, no. 3: 147-179. https://doi.org/10.3390/livers1030014

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop